Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 434-070-2 | CAS number: 268567-32-4
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
The substance is considered to be easily absorbed, metabolised and eliminated based on the reversible liver and kidney enlargement without histopathology correlates upon subacute oral exposure. This is consistent with the physico-chemical data that shows moderate water solubility and susceptability to acid-catalysed hydrolysis. The substance is considered to be non bioaccumulative.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
The physicochemistry of the substance and its molecular size impose that it will be readily absorbed through the gastro-intestinal tract. This is consistent with the adaptive liver enlargement observed in the subacute and subchronic oral toxicity study. Dermal absorption is also expected to be significant. Inhalative exposure to vapours is not of relevance as the substance has a very low vapour pressure (6.5×10–5Pa at 25°C), but upon exposure to contaminated aerosol particles it will be readily absorbed through respiratory tract. Upon absorption the substance will be rapidly distributed and excreted effectively.
Considering the adaptive liver enlargement observed in the repeated dose toxicity studies, the substance or one of the major components is likely to be subject to hepatic metabolism. This would be consistent with the influence of Arochlor-1254 induced rat liver S9 in the in-vitro clastogenicity study. Involvement of human CYP 1A2 was described for a substance of similar structure, and the analogue rat enzyme is highly inducible upon Arochlor-1254 treatment. Metabolism data is available for a structural analogue supporting the overall assessment of absence of bioaccumulation potential.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
